Machine learning for comprehensive forecasting of Alzheimer's Disease progression

Most approaches to machine learning from electronic health data can only predict a single endpoint.The ability to simultaneously simulate dozens of patient characteristics is a crucial step towardspersonalized medicine for Alzheimer's Disease. Here, we use an unsupervised machine learning modelcalled a Conditional Restricted Boltzmann Machine (CRBM) to simulate detailed patient trajectories.We use data comprising 18-month trajectories of 44 clinical variables from 1909 patients with MildCognitive Impairment or Alzheimer's Disease to train a model for personalized forecasting of diseaseprogression. We simulate synthetic patient data including the evolution of each sub-component ofcognitive exams, laboratory tests, and their associations with baseline clinical characteristics. Syntheticpatient data generated by the CRBM accurately refect the means, standard deviations, and correlationsof each variable over time to the extent that synthetic data cannot be distinguished from actual databy a logistic regression. Moreover, our unsupervised model predicts changes in total ADAS-Cog scoreswith the same accuracy as specifcally trained supervised models, additionally capturing the correlationstructure in the components of ADAS-Cog, and identifes sub-components associated with word recallas predictive of progression.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

CTAD 2020: Unlearn will present abstracts to demonstrate how Digital Twins enable smaller, more efficient trials

Blog

Announcing The Unlearn Opportunities Internship Program

Podcasts

UCSF Rosenman Institute - The Health Technology Podcast #59: Digital Twins for Clinical Trials

Charles Fisher: Digital Twins for Clinical Trials
Creating Opportunities for Students of Data Science and Business from Underrepresented Groups in STEM
Unlearn will present data from two separate abstracts demonstrating how Digital Twins can power novel trial designs and accelerate timelines.